Immatics N.V. Ordinary Shares (IMTX) Stock
NASDAQ · IMTX
8.40
Fundamentals
Market cap
$1.27B
Price / Earnings ratio
-4.8x
Price / Sales ratio
23.9x
Price / Book ratio
2.5x
Return on assets
-39.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
NeutralIMTXMay 12, 2026
Zacks Investment ResearchNeutral
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
IMTX

Zacks Investment Research
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
NeutralIMTXMay 6, 2026
Zacks Investment ResearchNeutral
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
IMTX

Zacks Investment Research
New Strong Buy Stocks for February 12th
NeutralIMTXFebruary 12, 2025
Zacks Investment ResearchNeutral
New Strong Buy Stocks for February 12th
IMTX

Zacks Investment Research
New Strong Buy Stocks for January 9th
NeutralIMTXJanuary 9, 2025
Zacks Investment ResearchNeutral
New Strong Buy Stocks for January 9th
IMTX
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
68M45M22M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
675M445M223M0
Revenue to Profit
2025$56.8M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-196.4M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
NeutralIMTXMay 12, 2026
Zacks Investment ResearchNeutral
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
IMTX

Zacks Investment Research
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
NeutralIMTXMay 6, 2026
Zacks Investment ResearchNeutral
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
IMTX

Zacks Investment Research
New Strong Buy Stocks for February 12th
NeutralIMTXFebruary 12, 2025
Zacks Investment ResearchNeutral
New Strong Buy Stocks for February 12th
IMTX

Zacks Investment Research
New Strong Buy Stocks for January 9th
NeutralIMTXJanuary 9, 2025
Zacks Investment ResearchNeutral
New Strong Buy Stocks for January 9th
IMTX

Proactive Investors
Immatics inks deal worth $120M to $1.7B with Moderna to boost cancer vaccine development
NeutralIMTXSeptember 11, 2023
Proactive InvestorsNeutral
Immatics inks deal worth $120M to $1.7B with Moderna to boost cancer vaccine development
IMTX

Market Watch
Immatics shares rise on Moderna cancer collaboration
NeutralIMTXSeptember 11, 2023
Market WatchNeutral
Immatics shares rise on Moderna cancer collaboration
IMTX

Reuters
Moderna, Immatics to work jointly on cancer vaccines
NeutralIMTXSeptember 11, 2023
ReutersNeutral
Moderna, Immatics to work jointly on cancer vaccines
IMTX

Market Watch
Immatics shares jump after investment from Bristol Myers Squibb
NeutralIMTXJuly 24, 2023
Market WatchNeutral
Immatics shares jump after investment from Bristol Myers Squibb
IMTX

Zacks Investment Research
BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
NeutralIMTXJune 3, 2022
Zacks Investment ResearchNeutral
BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
IMTX

Market Watch
Bristol Myers Squibb, Immatics expand CAR-T agreement
NeutralIMTXJune 2, 2022
Market WatchNeutral
Bristol Myers Squibb, Immatics expand CAR-T agreement
IMTX
About Immatics N.V. Ordinary Shares
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
SectorHealthcare
IndustryBiotechnology
Employees704
CEODr. Harpreet Singh Ph.D.
IPO DateJul 2, 2020
HeadquartersTübingen, Germany
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Harpreet Singh Ph.D. | CEO, MD, Member of Management Board & Executive Director | 1975 |
| Dr. Venkat Ramanan Ph.D. | Chief Financial Officer | 1970 |
| Ms. Amie Krause | Chief People Officer | 1973 |
| Dr. Hans-Georg Rammensee Ph.D. | Co-Founder & Member of the Scientific Advisory Board | — |
| Dr. Toni Weinschenk Ph.D. | Co-Founder & Chief Innovation Officer | 1970 |
| Mr. Steffen Walter Ph.D. | Chief Operations Officer | 1977 |
| Mr. Ephraim Hofsäß M.Sc. | Vice President of SEC Reporting & Accounting | — |
| Mr. James Pepin J.D. | General Counsel & Corporate Secretary | — |
| Ms. Lauren Schroeder | Vice President of Marketing | — |
| Dr. Carsten Reinhardt M.D., Ph.D. | Chief Development Officer | 1967 |
Fundamentals
Valuation
Market cap$1.27B
Price-to-sales ratio23.92
Price-to-book value2.50
Price-earnings ratio-4.80
Return on Equity-47.00%
Return on Sales-577.00%
Return on Assets-39.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.83
Income Statement
Average volume696,037
EBITDA$-232.09M
1 year high (52w)$12.41
1 year low (52w)$6.90
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.2 | +9.8 | +6.7 | -9.1 | -12.1 | +5.7 | -11.2 |



